This page was automatically translated and accurateness of translation is not guaranteed. Please refer to the English version for a source text.

3D ECG for Detection of Cardiomyopathy

3D ECG for Detection of Cardiomyopathy in Heart Failure

Sponzoři

Hlavní sponzor: University Hospital, Essen

Zdroj University Hospital, Essen
Stručné shrnutí

There is existing data in the literature that suggests an additional predictive value of three dimensional ECG with respect to the presence of electrical abnormalities and for an existing cardiac disease. Especially regarding patients who suffered from a myocardial infarction in the past (post MI patients), evidence has been provided for a potential association of 3D repolarisation abnormalities and incidence of sudden cardiac death (SCD). In addition, there is some vague evidence of so called 3D ECG and prediction of coronary artery disease. This 3D ECG device is using the technology of 3D ECG vector loops and is assessing the variability of these ECG vector loops in the 3-dimensional space. Based on these data, the parameters of 3D ECG are suggested to carry certain value to predict or to identify individuals already suffering from a cardiac disease or being at risk experiencing a cardiac event in the future. In this context we performed a preliminary study with 3D-ECG device in healthy volunteers evaluating the robustness of this method with respect to reproducibility, intra- and intra-observer variability which could be confirmed. We thus postulate that the 3D ECG technology might bear the potential to serve as a sufficient screening method for diagnosing cardiomyopathy in patients with an unknown heart failure etiology.

Celkový stav Recruiting
Počáteční datum 2021-03-14
Datum dokončení 2021-10-14
Datum primárního dokončení 2021-09-14
Typ studie Observational
Primární výsledek
Opatření Časové okno
Cardiomyopathy Within 24 hours
Zápis 175
Stav
Zásah

Typ intervence: Diagnostic Test

Název intervence: 3D-ECG

Popis: Patient recieves 3D-ECG Assessement

Štítek skupiny paží: Patient recieving 3D-ECG-Evaluation

Způsobilost

Metoda vzorkování:

Probability Sample

Kritéria:

Inclusion Criteria: - Age >18 Years - Established diagnosis heart failure and suggested cardiomyopathy Exclusion Criteria: - Patients unable to sign informed consent - Pacemaker-stimulated ECG

Rod:

All

Minimální věk:

18 Years

Maximální věk:

N/A

Zdraví dobrovolníci:

No

Celkově oficiální
Příjmení Role Přidružení
Reza Wakili, Prof. Principal Investigator University Hospital, Essen
Celkový kontakt

Příjmení: Reza Wakili, Prof.

Telefon: 00492017234802

E-mailem: reza.wakili@uk-essen.de

Umístění
Zařízení: Postavení: Kontakt: Kontaktujte zálohování: West-German Heart and Vascular Center Essen, University Hospital Essen Reza Wakili, Prof. Dr. 0201 723 4802 reza.wakili@uk-essen.de
Země umístění

Germany

Datum ověření

2021-04-01

Odpovědná strana

Typ: Sponsor

Rozšířil přístup No
Podmínka Procházet
Skupina paží

Označení: Patient recieving 3D-ECG-Evaluation

Údaje o pacientovi No
Informace o studijním designu

Pozorovací model: Cohort

Časová perspektiva: Prospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

analytics

Klinické studie na Heart Failure

3
Předplatit